Marie Carlo
@pearldaily
Followers
167
Following
212
Media
2
Statuses
358
Medical oncologist | genitourinary cancers and genetics @sloan_kettering. Used to tweet clinical pearls 🚫 current medical advice. Views my own. 🇵🇷
Joined September 2009
RT @EUplatinum: Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated w….
0
14
0
Congrats to @HongTruongMD and Kelsey Breen for taking the lead in this amazing effort! Will help us better counsel PC pts who come in with a tumor profiling report, asking how likely it is they have an inherited cancer syndrome.
Excited to share our study showing how often germline variants are uncovered by prostate tumor-only sequencing
0
0
3
RT @arihakimi: So excited to share our latest work in @CD_AACR led by two incredible folks @LynVuong and @UrologyM….
aacrjournals.org
Intratumor myeloid inflammation independently predicts metastatic recurrence after nephrectomy in clear-cell renal cell carcinoma (ccRCC) and can be therapeutically targeted in a novel metastatic...
0
26
0
RT @ChungHanLee3: Retrospective study showing benefit of TKI/ICI in FH-deficient RCC in @EUplatinum Would love to s….
0
1
0
RT @ChungHanLee3: Negative study for MEDI0680 + Durvalumab vs. Nivolumab in RCC, but really interesting to see decrease in ctDNA at 4 weeks….
0
10
0
RT @NeilVasan: This was a pleasure to write with @CantleyLab and we hope this Review will be useful for oncologists, translational scientis….
0
16
0
RT @OncLive: Experts review a clinical scenario of intermediate- and poor-risk renal cell carcinoma that is managed with ipilimumab-nivolum….
0
3
0
RT @AmerUrological: 🔔TODAY! at 7PM ET!!🔔 Join Drs. @wandering_gu, @pearldaily, @EHeath4100, & Brian Helfand for this FREE live virtual CME….
0
4
0
RT @JCO_ASCO: Cabozantinib + Nivolumab in non-clear cell #RenalCellCarcinoma.🗒️ Phase II trial.🧑🏽🤝🧑🏽 n=47 .🙌 Response rate 48%.🤩 Response….
0
16
0
RT @ChungHanLee3: Cabozantinib plus Nivolumab shows a 48% objective response rate in a phase II study in non-clear cell RCC. @JCO_ASCO @mot….
ascopubs.org
PURPOSETo assess the efficacy and safety of cabozantinib plus nivolumab in a phase II trial in patients with non–clear-cell renal cell carcinoma (RCC).PATIENTS AND METHODSPatients had advanced...
0
36
0
RT @arihakimi: Excited to share our report from a Phase II trial of neoadjuvant Nivolumab in high risk localized #kidneycancer published to….
0
16
0
Go Blue!.
Was a real privilege to get a chance to give an IN PERSON talk again at the amazing @UMichUrology . Wonderful to see former fellows @smkaff and @BCottaMD and my good friend @wandering_gu . Appreciated the swag bag too!
0
0
1
RT @ashishkjha: When folks think about highly vaccinated places in America. They think Vermont or CT or MA. Those places are good. But not….
0
8K
0
6/ Many thanks to @motzermd, @unclassified1, Ines Nikolovski, Sujata Patil, Andrea Knezevic, @MVossMD, @DrDarrenFeldman, @arihakimi, and @EdReznik, and to all patients involved.
0
1
4
5/ Remaining questions:.Response to VEGF/IO combinations? 1/1 patient in our cohort had a PR with lenvatinib+pembrolizumab. In ph2 cabozantinib+nivolumab trial presented by @ChungHanLee3 at #ASCO21- 4 of 5 RCC with FH mutations had a PR.
0
0
3
4/ On retrospective evaluation, responses were seen with mTOR/VEGF combination (ORR 44%), VEGF monotherapy (ORR 20%), but not with checkpoint inhibitor monotherapy (n=8, ORR 0%).
0
0
2
3/ In 32 pts with FH-RCC, 16% had biallellic somatic FH loss and no germline FH mutation. No molecular/clinical differences were found (although small numbers). Compared to clear cell RCC, FH-RCC had lower mutation count but higher fraction of genome altered.
0
0
2
2/ FH-RCC is a rare type of kidney cancer associated with germline FH mutations. The prevalence of FH-RCC in pts without germline mutations and response to standard RCC systemic therapy is not well described. Recent review by Aikseng Ooi: .
0
0
2
1/ Delighted to share our work on FH-deficient RCC @CCR_AACR . Led by former fellow, now attending @jgleesonirl .
0
5
10